Daxor Corporation to Showcase the Benefits of BVA-100® Guided Care at the American Association of Heart Failure Nurses (AAHFN) 19th Annual Meeting
20 Junho 2023 - 9:00AM
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume
measurement technology, announces today it will exhibit at the
American Association of Heart Failure Nurses (AAHFN) 19th Annual
Meeting from June 29 - July 1, 2023 at the Boston Marriott Copley
Place.
“The AAHFN Annual Meeting is an exciting
opportunity to generate awareness and educate nurses and other
health professionals interested in heart failure on the use of our
blood volume technology. Our diagnostic has been proven to reduce
heart failure 30-day mortality by 82% and 30-day readmissions by
56%, and results in a 55% reduction in length of stay when done on
admission,” said Kathryn Kornafel, VP, Marketing and Commercial
Development.
Daxor will also be sponsoring a focus group
hosted by Dr. Robin J. Trupp, Ph.D., MSN, FHSA, FAHA, founding
member and former President of AAHFN, to allow nurses from across
the continuum of practice to discuss openly and learn from each
other their experiences and the benefits of blood volume
analysis.
The AAHFN is a specialty organization dedicated
to advancing nursing education, clinical practice, and research to
improve heart failure patient outcomes. The company will be
exhibiting at Booth 275. Register for the event HERE.
About Daxor
Corporation
Daxor Corporation (Nasdaq: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the first diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing multicenter trials in
the areas of COVID-19 and heart failure treatment with support from
the NIH and is under contract developing analyzers to improve
combat casualty care with the U.S. Department of Defense. Daxor's
mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal
blood volume for all. For more information, please visit our
website at Daxor.com. Sign up to receive news on Daxor’s innovative
technology HERE.
Forward-Looking
StatementsCertain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret
ShapiroSr. Managing Partner, CORE
IR1-516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Daxor (NASDAQ:DXR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024